ClinConnect ClinConnect Logo
Search / Trial NCT07069218

Hydroxyapatite Toothpastes and Enamel Remineralization:

Launched by UNIVERSITY OF PAVIA · Jul 5, 2025

Trial Information

Current as of September 09, 2025

Recruiting

Keywords

Hydroxyapatite Toothpaste Enamel Remineralization Diagn Ocam Diagn Odent Tooth Erosion Dentin Sensitivity Dental Plaque Oral Health Randomized Controlled Trial Preventive Dentistry

ClinConnect Summary

This clinical trial is looking at how well two different toothpastes that contain a mineral called hydroxyapatite help repair and strengthen early damage to tooth enamel, which is the hard, outer layer of your teeth. The study compares Biorepair® Total Protection Plus, which has special tiny particles designed to mimic natural tooth minerals, with Bioniq® Repair, a more traditional hydroxyapatite toothpaste. The goal is to see if one toothpaste can better help rebuild and protect enamel, reduce tooth sensitivity, and improve overall dental health.

Children and teenagers between 6 and 18 years old who have early signs of enamel damage but not severe tooth problems may be eligible to join. To take part, they need to have fully grown permanent first molars and upper front teeth, be able to follow instructions, and have consent from a parent or guardian. Participants will use their assigned toothpaste twice a day for six months and visit the dentist every three months for cleanings and check-ups. Throughout the study, dental health will be carefully monitored using special tools and questionnaires to see how well the toothpastes work and how satisfied participants are with the treatment. This research will help dentists understand which toothpaste might be better for protecting and repairing young teeth.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subjects aged between 6 and 18 years
  • Ability to understand and follow instructions in Italian or English
  • Signed written informed consent provided by the parent/legal guardian and assent from the minor
  • Good cooperation and adherence to clinical instructions
  • Fully erupted permanent first molars and upper central incisors in good general condition
  • DIAGNOdent Pen baseline values in the C1 (0-12) or C2 (13-24) range
  • Exclusion Criteria:
  • DIAGNOdent Pen values greater than 25
  • Ongoing systemic antibiotic therapy
  • Presence of sealants or composite restorations on first permanent molars or upper central incisors
  • Severe enamel alterations such as molar-incisor hypomineralization (MIH), fluorosis, or extensive white/brown spot lesions
  • Poor motivation or limited compliance with study procedures

About University Of Pavia

The University of Pavia, a prestigious institution renowned for its commitment to academic excellence and research innovation, serves as a prominent clinical trial sponsor. With a strong emphasis on advancing medical knowledge and improving patient care, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research. Collaborating with leading healthcare professionals and institutions, the University of Pavia is dedicated to exploring novel therapeutic approaches and fostering the translation of scientific discoveries into clinical practice, ultimately aiming to enhance health outcomes and contribute to the global medical community.

Locations

Pavia, Lombardy, Italy

Patients applied

0 patients applied

Trial Officials

Andrea Scribante, Associate Professor

Principal Investigator

University of Pavia

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported